Plasma level of N-terminal pro brain natriuretic peptide (NT-proBNP) in elderly population in Poland - The PolSenior Study

Experimental Gerontology

Volumn 48, Issue 9, 2013, Pages 852-857

  Nadrowski, P ^a   Chudek, J ^b   Grodzicki, T ^c   Mossakowska, M ^d   Skrzypek, M ^b   Wiecek, A ^b   Zdrojewski, T ^e   Kozakiewicz, K ^a  

^a Upper Silesian Heart Center Katowice   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

^e MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Elderly population; Epidemiological description; Heart failure; NT proBNP; PolSenior Study

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT;

ADULT; AGE; AGING; ARTICLE; BLOOD SAMPLING; CHEMILUMINESCENCE IMMUNOASSAY; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; ELDERLY CARE; ELECTROCHEMICAL ANALYSIS; FEMALE; GERIATRIC ASSESSMENT; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; POLAND; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SOCIOECONOMICS; UPREGULATION; URINALYSIS;

ELDERLY POPULATION; EPIDEMIOLOGICAL DESCRIPTION; HEART FAILURE; NT-PROBNP; POLSENIOR STUDY;

AGED; AGED, 80 AND OVER; AGING; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; DIABETES MELLITUS; DRUG UTILIZATION; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPERTENSION; MALE; NATRIURETIC PEPTIDE, BRAIN; OBESITY; PEPTIDE FRAGMENTS; POLAND; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; SEX CHARACTERISTICS;

EID: 84880368414     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2013.05.060     Document Type: Article

References (26)

1. Almirez R., Protter A.A. Clearance of human brain natriuretic peptide in rabbits; effect of the kidney, the natriuretic peptide clearance receptor, and peptidase activity. J. Pharmacol. Exp. Ther. 1999, 289:976-980.
2. Baggish A.L., Cameron R., Anwaruddin S., Chen A.A., Krauser D.G., Tung R., Januzzi J.L. A clinical and biochemical critical pathway for the evaluation of patients with suspected acute congestive heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) algorithm. Crit. Pathw. Cardiol. 2004, 3:171-176.
3. Bledowski P., Mossakowska M., Chudek J., Grodzicki T., Milewicz A., Szybalska A., Wieczorowska-Tobis K., Wiecek A., Bartoszek A., Dabrowski A., Zdrojewski T. Medical, psychological and socioeconomic aspects of aging in Poland: assumptions and objectives of the PolSenior project. Exp. Gerontol. 2011, 46:1003-1009.
4. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001, 357:1385-1390.
5. deFilippi C.R., Christenson R.H. B-type natriuretic peptide (BNP)/NT-proBNP and renal function: is the controversy over?. Clin. Chem. 2009, 55:1271-1273.
6. Dessi-Fulgheri P., Sarzani R., Serenelli M., Tamburrini P., Spagnolo D., Giantomassi L., Espinosa E., Rappelli A. Low calorie diet enhances renal, hemodynamic, and humoral effects of exogenous atrial natriuretic peptide in obese hypertensives. Hypertension 1999, 33:658-662.
7. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J., Ponikowski P., Poole-Wilson P.A., Stromberg A., van Veldhuisen D.J., Atar D., Hoes A.W., Keren A., Mebazaa A., Nieminen M., Priori S.G., Swedberg K., E.S.C.C.F.P.Guidelines ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J. 2008, 29:2388-2442.
8. Fedyk-Lukasik M., Zdrojewski T., Wizner B., Opolski G., Dubiel J., Stompor M., Wyrzykowski B., Mogilnaya I., Marchel M., Grodzicki T. Heart failure management in Poland: The National Cardiovascular Disease Prevention and Treatment Program POLKARD, edition 2003-2005. Cardiol. J. 2007, 14:552-560.
9. Kelder J.C., Cramer M.J., van Wijngaarden J., van Tooren R., Mosterd A., Moons K.G., Lammers J.W., Cowie M.R., Grobbee D.E., Hoes A.W. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation 2011, 124:2865-2873.
10. Licata G., Volpe M., Scaglione R., Rubattu S. Salt-regulating hormones in young normotensive obese subjects. Effects of saline load. Hypertension 1994, 23:I20-I24.
11. Luchner A., Hengstenberg C., Lowel H., Buchner S., Schunkert H., Riegger G.A., Holmer S. NT-ProBNP in outpatients after myocardial infarction: interaction between symptoms and left ventricular function and optimized cut-points. J. Card. Fail. 2005, 11:S21-S27.
12. Morabito D., Vallotton M.B., Lang U. Obesity is associated with impaired ventricular protein kinase C-MAP kinase signaling and altered ANP mRNA expression in the heart of adult Zucker rats. J. Investig. Med. 2001, 49:310-318.
13. Nakao K., Mukoyama M., Hosoda K., Suga S., Ogawa Y., Saito Y., Shirakami G., Arai H., Jougasaki M., Imura H. Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. Can. J. Physiol. Pharmacol. 1991, 69:1500-1506.
14. O'Donoghue M., Kenney P., Oestreicher E., Anwaruddin S., Baggish A.L., Krauser D.G., Chen A., Tung R., Cameron R., Januzzi J.L. Usefulness of aminoterminal pro-brain natriuretic peptide testing for the diagnostic and prognostic evaluation of dyspneic patients with diabetes mellitus seen in the emergency department (from the PRIDE Study). Am. J. Cardiol. 2007, 100:1336-1340.
15. Patton K.K., Ellinor P.T., Heckbert S.R., Christenson R.H., DeFilippi C., Gottdiener J.S., Kronmal R.A. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation 2009, 120:1768-1774.
16. Raizada V., Thakore K., Luo W., McGuire P.G. Cardiac chamber-specific alterations of ANP and BNP expression with advancing age and with systemic hypertension. Mol. Cell. Biochem. 2001, 216:137-140.
17. Raymond I., Groenning B.A., Hildebrandt P.R., Nilsson J.C., Baumann M., Trawinski J., Pedersen F. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003, 89:745-751.
18. Rivera M., Talens-Visconti R., Salvador A., Bertomeu V., Miro V., Garcia de Burgos F., Climent V., Cortes R., Paya R., Perez-Bosca J.L., Mainar L., Jordan A., Sogorb F., Cosin J., Mora V., Diago J.L., Marin F. NT-proBNP levels and hypertension. Their importance in the diagnosis of heart failure. Rev. Esp. Cardiol. 2004, 57:396-402.
19. Sarzani R., Dessi-Fulgheri P., Paci V.M., Espinosa E., Rappelli A. Expression of natriuretic peptide receptors in human adipose and other tissues. J. Endocrinol. Invest. 1996, 19:581-585.
20. Sayama H., Nakamura Y., Saito N., Kinoshita M. Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal?. Coron. Artery Dis. 1999, 10:537-540.
21. Scheven L., de Jong P.E., Hillege H.L., Lambers Heerspink H.J., van Pelt L.J., Kootstra J.E., Bakker S.J., Gansevoort R.T., P.S.Group High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. Eur. Heart J. 2012, 33:2272-2281.
22. Silver M.A., Maisel A., Yancy C.W., McCullough P.A., Burnett J.C., Francis G.S., Mehra M.R., Peacock W.F.t., Fonarow G., Gibler W.B., Morrow D.A., Hollander J., B.N.P.C.Panel BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest. Heart Fail. 2004, 10:1-30.
23. Srisawasdi P., Vanavanan S., Charoenpanichkit C., Kroll M.H. The effect of renal dysfunction on BNP, NT-proBNP, and their ratio. Am. J. Clin. Pathol. 2010, 133:14-23.
24. Talwar S., Downie P.F., Squire I.B., Davies J.E., Barnett D.B., Ng L.L. Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. Eur. J. Heart Fail. 2001, 3:15-19.
25. Vaes B., Gruson D., van Pottelbergh G., Pasquet A., Mathed C., Adriaensen W., Rezzoug N., Vanoverschelde J.-L., Degryse J. The impact of confounders on the test performance of natriuretic peptides for cardiac dysfunction in subjects aged 80 and older. Peptides 2012, 38:118-126.
26. Yano Y., Katsuki A., Gabazza E.C., Ito K., Fujii M., Furuta M., Tuchihashi K., Goto H., Nakatani K., Hori Y., Sumida Y., Adachi Y. Plasma brain natriuretic peptide levels in normotensive noninsulin-dependent diabetic patients with microalbuminuria. J. Clin. Endocrinol. Metab. 1999, 84:2353-2356.